Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Body Composition and Fluid Status in Cardiovascular Rehabilitation Patients with Coronary Artery Disease and Heart Failure
2024

Effects of SGLT-2 Inhibitors on Body Composition in Heart Patients

Sample size: 171 publication 10 minutes Evidence: moderate

Author Information

Author(s): De La Flor José C., Coto Morales Blanca, Basabe Elena, Rey Hernandez María, Zamora González-Mariño Rocío, Rodríguez Tudero Celia, Benites Flores Irwing, Espinoza Carlos, Cieza Terrones Michael, Cigarrán Guldris Secundino, Hernández Vaquero Jesús

Primary Institution: Hospital Central de la Defensa Gómez Ulla, Madrid, Spain

Hypothesis

What are the effects of SGLT-2 inhibitors on body composition and fluid status in cardiovascular rehabilitation patients?

Conclusion

SGLT-2 inhibitors help reduce body fat and extracellular volume without losing lean body mass in heart failure patients.

Supporting Evidence

  • Patients treated with SGLT-2 inhibitors lost more weight than those who were not treated.
  • SGLT-2 inhibitors significantly reduced extracellular water and body fat mass.
  • Patients on SGLT-2 inhibitors did not lose lean body mass during the study.
  • Significant reductions in systolic and diastolic blood pressure were observed in the SGLT-2 inhibitor group.
  • NT-proBNP levels improved significantly in patients treated with SGLT-2 inhibitors.

Takeaway

This study shows that a type of medicine called SGLT-2 inhibitors can help heart patients lose fat and water weight without losing muscle.

Methodology

This was a retrospective, observational longitudinal cohort study analyzing body composition and fluid status using bioelectrical impedance analysis over 12 weeks.

Potential Biases

Potential bias due to the observational nature and disparity in group sizes.

Limitations

The study had a small sample size and was observational with a short follow-up period.

Participant Demographics

71.4% male, mean age 66.9 years, with high comorbidity rates including 32.8% having type 2 diabetes.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/medicina60122096

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication